Recaticimab - Jiangsu Hengrui Medicine Co.
Alternative Names: SHR-1209Latest Information Update: 09 Jun 2025
At a glance
- Originator Jiangsu Hengrui Medicine Co.
- Class Antihyperlipidaemics; Monoclonal antibodies
- Mechanism of Action PCSK9 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Registered Hypercholesterolaemia; Hyperlipidaemia
- Phase II Hyperlipoproteinaemia type IIa
Most Recent Events
- 03 Jun 2025 Shanghai East Hospital plans to initiate a phase III trial for Stroke in China (SC) (NCT07002476)
- 20 Feb 2025 Jiangsu HengRui Medicine plans to initiate a phase I trial for Hypercholesterolemia (In volunteers) in China (SC) (NCT06837077)
- 13 Jan 2025 Jiangsu Hengrui Medicine Co. plans to launch recaticimab for Hypercholesterolaemia and Hyperlipidaemia (SC)